Softwr

Healthcare · head to head

Paige vs Tebra

Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite
Tebra logo

Tebra

Healthcare

Practice management combining EHR, billing and patient engagement for independent practices

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.; Tebra no pricing amounts published; custom quote required based on practice configuration
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Paige and Tebra actually diverge.

Attributes where Paige and Tebra differ
AttributePaigeTebra
PlatformsWeb, Cloud, On-premiseWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

Only in Tebra

Nothing recorded that Paige does not also cover.

What people use each for

The jobs each tool is most often brought in to do.

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Tebra
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Tebra
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Tebra
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Tebra

Tebra

  • Consolidating scheduling, charting, billing into single systemnot Paige
  • Automating claims submission and denial managementnot Paige
  • Reducing appointment no-shows through automated remindersnot Paige
  • Reducing documentation time to five minutes with AInot Paige
  • E-prescribing controlled substances with PDMP and EPCSnot Paige

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Tebra

  • No pricing amounts published; custom quote required based on practice configuration
  • Pricing based on per-provider licensing model with additional costs for EPCS setup and PDMP integration

Pricing, plan by plan

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Tebra

On request

No published plan breakdown. See the Tebra review.

Which should you pick?

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Choose Tebra if

Nothing in the data separates Tebra from Paige on the points above - pick on price and on how each one feels to use.

Tebra review

Questions people ask

Is Paige or Tebra better?
Neither clearly leads. Paige starts at On request and Tebra at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Paige or Tebra?
Paige starts at On request and Tebra at On request.
Does Paige or Tebra run on more platforms?
Paige runs on Web, Cloud, On-premise. Tebra runs on Web.
What is Paige best used for?
Paige is most often used for a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable, a pathology department already digitised that wants a documented safety net against missed small foci of cancer, a hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting, a pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability. Of those, a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable and a pathology department already digitised that wants a documented safety net against missed small foci of cancer are not what Tebra is typically brought in for.
What can Paige do that Tebra cannot?
Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Tebra: How does Tebra's pricing model work?

Pricing is based on the number of clinical providers rather than user seats. Non-clinical staff get unlimited access at no additional cost. Low-volume providers billing under 100 claims monthly receive lower-tier pricing.

Source
Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Tebra: What are the setup and integration costs beyond the monthly fee?

Electronic Prescribing Controlled Substances (EPCS) setup costs approximately $75 per provider as a one-time fee. PDMP integration costs $500 one-time per facility plus approximately $50 per user per year.

Source
Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Tebra: Are there volume discounts for practices using multiple modules?

Yes, bundled pricing and volume incentives are available for multi-module adoption. Practices can request a personalized quote to see potential savings.

Source
Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Tebra: Does Tebra offer published pricing or is a quote always required?

Tebra does not publish specific monthly costs. Pricing varies depending on the number of providers, platform features needed, and implementation requirements. A personalized quote is required to get pricing.

Source
Share

Related pages

More on Paige

More on Tebra

Keep looking

Other head to heads